Search Results - "Kastelein, J. J. P"

Assessment of atherosclerosis: the role of flow-mediated dilatation by Charakida, Marietta, Masi, Stefano, Lüscher, Thomas F., Kastelein, John J.P., Deanfield, John E.

“…Evidence suggests that endothelial dysfunction is on the causal pathway for both atherogenesis and destabilization of established plaques. In this review, the…”
Get full text

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus by Besseling, Joost, Kastelein, John J. P, Defesche, Joep C, Hutten, Barbara A, Hovingh, G. Kees

“…IMPORTANCE: Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In…”
Get full text

C-reactive protein is a mediator of cardiovascular disease by Bisoendial, Radjesh J., Boekholdt, S. Matthijs, Vergeer, Menno, Stroes, Erik S.G., Kastelein, John J.P.

“…C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events…”
Get full text

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies by Banach, Maciej, Serban, Corina, Sahebkar, Amirhossein, Mikhailidis, Dimitri P, Ursoniu, Sorin, Ray, Kausik K, Rysz, Jacek, Toth, Peter P, Muntner, Paul, Mosteoru, Svetlana, García-García, Hector M, Hovingh, G Kees, Kastelein, John J P, Serruys, Patrick W

“…Virtual histology intravascular ultrasound (VH-IVUS) imaging is an innovative tool for the morphological evaluation of coronary atherosclerosis. Evidence for…”
Get full text

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis by Preiss, David, Seshasai, Sreenivasa Rao Kondapally, Welsh, Paul, Murphy, Sabina A, Ho, Jennifer E, Waters, David D, DeMicco, David A, Barter, Philip, Cannon, Christopher P, Sabatine, Marc S, Braunwald, Eugene, Kastelein, John J. P, de Lemos, James A, Blazing, Michael A, Pedersen, Terje R, Tikkanen, Matti J, Sattar, Naveed, Ray, Kausik K

“…CONTEXT A recent meta-analysis demonstrated that statin therapy is associated with excess risk of developing diabetes mellitus. OBJECTIVE To investigate…”
Get full text

Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women by RANA, Jamal S, ARSENAULT, Benoit J, MATTHIJS BOEKHOLDT, S, DESPRES, Jean-Pierre, COTE, Mélanie, TALMUD, Philippa J, NINIO, Ewa, JUKEMA, J. Wouter, WAREHAM, Nicholas J, KASTELEIN, John J. P, KHAW, Kay-Tee

“…The aim of this study was to determine the contribution of physical activity and abdominal obesity to the variation in inflammatory biomarkers and incident…”
Get full text

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders by Ward, E. Sally, Gelinas, Deborah, Dreesen, Erwin, Van Santbergen, Jolien, Andersen, Jan Terje, Silvestri, Nicholas J., Kiss, Joseph E., Sleep, Darrell, Rader, Daniel J., Kastelein, John J. P., Louagie, Els, Vidarsson, Gestur, Spriet, Isabel

“…Serum albumin (SA), the most abundant soluble protein in the body, maintains plasma oncotic pressure and regulates the distribution of vascular fluid and has a…”
Get full text

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial by Ridker, Paul M, Prof, Genest, Jacques, Prof, Boekholdt, S Matthijs, MD, Libby, Peter, Prof, Gotto, Antonio M, Prof, Nordestgaard, Børge G, Prof, Mora, Samia, MD, MacFadyen, Jean G, BA, Glynn, Robert J, ScD, Kastelein, John JP, Prof

“…Summary Background HDL-cholesterol concentrations are inversely associated with occurrence of cardiovascular events. We addressed, using the JUPITER trial…”
Get full text

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis by Boekholdt, S. Matthijs, Arsenault, Benoit J, Mora, Samia, Pedersen, Terje R, LaRosa, John C, Nestel, Paul J, Simes, R. John, Durrington, Paul, Hitman, Graham A, Welch, K. M. A, DeMicco, David A, Zwinderman, Aeilko H, Clearfield, Michael B, Downs, John R, Tonkin, Andrew M, Colhoun, Helen M, Gotto, Antonio M, Ridker, Paul M, Kastelein, John J. P

“…CONTEXT The associations of low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB)…”
Get full text

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial by Ridker, Paul M, Prof, Dr, Danielson, Eleanor, MIA, Fonseca, Francisco AH, MD, Genest, Jacques, Prof, Gotto, Antonio M, Prof, Kastelein, John JP, Prof, Koenig, Wolfgang, Prof, Libby, Peter, Prof, Lorenzatti, Alberto J, Prof, MacFadyen, Jean G, BA, Nordestgaard, Børge G, Prof, Shepherd, James, Prof, Willerson, James T, Prof, Glynn, Robert J, ScD

“…Summary Background Statins lower high-sensitivity C-reactive protein (hsCRP) and cholesterol concentrations, and hypothesis generating analyses suggest that…”
Get full text

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events by Barter, Philip, Gotto, Antonio M, LaRosa, John C, Maroni, Jaman, Szarek, Michael, Grundy, Scott M, Kastelein, John J.P, Bittner, Vera, Fruchart, Jean-Charles

“…In a post hoc analysis of the Treating to New Targets study, high-density lipoprotein cholesterol levels in patients receiving statin therapy were shown to be…”
Get full text

Seven Lipoprotein Lipase Gene Polymorphisms, Lipid Fractions, and Coronary Disease: A HuGE Association Review and Meta-Analysis by Sagoo, Gurdeep S., Tatt, Iain, Salanti, Georgia, Butterworth, Adam S., Sarwar, Nadeem, van Maarle, Merel, Jukema, J. Wouter, Wiman, Björn, Kastelein, John J. P., Bennet, Anna M., de Faire, Ulf, Danesh, John, Higgins, Julian P. T.

“…Lipoprotein lipase (LPL) is a key enzyme in lipoprotein metabolism and a major candidate gene for coronary heart disease (CHD). The authors assessed…”
Get full text

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal by Huijgen, Roeland, Kindt, Iris, Verhoeven, Sjoerd B J, Sijbrands, Eric J G, Vissers, Maud N, Kastelein, John J P, Hutten, Barbara A

“…The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and…”
Get full text

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia by Kastelein, John J.P, Akdim, Fatima, Stroes, Erik S.G, Zwinderman, Aeilko H, Bots, Michiel L, Stalenhoef, Anton F.H, Visseren, Frank L.J, Sijbrands, Eric J.G, Trip, Mieke D, Stein, Evan A, Gaudet, Daniel, Duivenvoorden, Raphael, Veltri, Enrico P, Marais, A. David, de Groot, Eric

“…In a 2-year clinical trial, the addition of ezetimibe to simvastatin had no effect on the progression of atherosclerosis, as measured by carotid-artery…”
Get full text

A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism by Glynn, Robert J, Danielson, Eleanor, Fonseca, Francisco A.H, Genest, Jacques, Gotto, Antonio M, Kastelein, John J.P, Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J, MacFadyen, Jean G, Nordestgaard, Børge G, Shepherd, James, Willerson, James T, Ridker, Paul M

“…In this secondary analysis of data from JUPITER, rosuvastatin, as compared with placebo, resulted in a reduced risk of symptomatic venous thromboembolism…”
Get full text

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study by Versmissen, Jorie, Oosterveer, Daniëlla M, Yazdanpanah, Mojgan, Defesche, Joep C, Basart, Dick C G, Liem, Anho H, Heeringa, Jan, Witteman, Jacqueline C, Lansberg, Peter J, Kastelein, John J P, Sijbrands, Eric J G

“…Objective To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia.Design Cohort study…”
Get full text

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers by Arsenault, Benoit J, Barter, Philip, DeMicco, David A, Bao, Weihang, Preston, Gregory M, LaRosa, John C, Grundy, Scott M, Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K, Shepherd, James, Waters, David D, Kastelein, John J P

“…Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the…”
Get full text

Effects of Torcetrapib in Patients at High Risk for Coronary Events by Barter, Philip J, Caulfield, Mark, Eriksson, Mats, Grundy, Scott M, Kastelein, John J.P, Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D, Shear, Charles L, Revkin, James H, Buhr, Kevin A, Fisher, Marian R, Tall, Alan R, Brewer, Bryan

“…Torcetrapib, a cholesteryl ester transfer protein inhibitor, markedly raises levels of high-density lipoprotein cholesterol. Unexpectedly, in the ILLUMINATE…”
Get full text

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease: A Randomized Controlled Trial by NICHOLLS, Stephen J, GORDON, Allan, JOHANSSON, Jan, WOLSKI, Kathy, BALLANTYNE, Christie M, KASTELEIN, John J. P, TAYLOR, Allen, BORGMAN, Marilyn, NISSEN, Steven E

“…The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent designed to enhance apolipoprotein (apo)…”
Get full text

Genetic Variant of the Scavenger Receptor BI in Humans by Vergeer, Menno, Korporaal, Suzanne J.A, Franssen, Remco, Meurs, Illiana, Out, Ruud, Hovingh, G. Kees, Hoekstra, Menno, Sierts, Jeroen A, Dallinga-Thie, Geesje M, Motazacker, Mohammad Mahdi, Holleboom, Adriaan G, Van Berkel, Theo J.C, Kastelein, John J.P, Van Eck, Miranda, Kuivenhoven, Jan Albert

“…In a family with high HDL, a genetic mutation was identified. In addition to higher HDL levels, carriers had reduced cholesterol efflux from macrophages,…”
Get full text